Targeting a key factor to treat breast cancers
FoXM1 inhibition: a novel therapeutic avenue to treat breast cancers
This study is looking at how breast cancer cells fix their damaged DNA so they can keep growing and resist treatments, and it aims to find new ways to help patients with tough-to-treat breast cancer by blocking a key factor involved in this repair process.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Texas Hlth Science Center NIH-funded |
| Lab location | 1 site (San Antonio, United States) |
| Project ID | NIH-10749015 on NIH RePORTER |
What this research studies
This research investigates how breast cancer cells repair DNA damage, which allows them to survive and resist treatment. It focuses on inhibiting a specific factor that plays a critical role in multiple DNA repair pathways, potentially leading to improved outcomes for patients with aggressive forms of breast cancer. By understanding the mechanisms behind DNA repair in cancer cells, the research aims to develop new therapeutic strategies that could enhance the effectiveness of existing treatments. Patients may benefit from novel therapies that target these DNA repair processes.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with aggressive breast cancer subtypes, such as triple-negative breast cancer or estrogen receptor-positive breast cancer.
Not a fit: Patients with early-stage breast cancer that is not aggressive or those who have already responded well to standard treatments may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for breast cancer, particularly for patients with aggressive subtypes.
How similar studies have performed: Other research has shown promising results in targeting DNA repair mechanisms in cancer cells, indicating that this approach could be effective.
Where this research is happening
San Antonio, United States
- University of Texas Hlth Science Center — San Antonio, United States (Active)
Researchers
- Principal investigator: Rao, Manjeet Kumar — University of Texas Hlth Science Center
- Study coordinator: Rao, Manjeet Kumar
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.